Pharma Journalist -

Takeda announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and its subsidiary HUTCHMED Limited, for the further…
Read More...

Over the last few decades, immunotherapy has developed at a rapid rate in the treatment of cancer where neoantigens are the lates breakthrough in tumour immunotherapy. Today, it is…
Read More...

BioCryst Pharmaceuticals, Inc. announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO (berotralstat) in Central and Eastern Europe…
Read More...

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of…
Read More...

Blueprint Medicines Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental new drug application for AYVAKIT (avapritinib) for the…
Read More...

Evaxion Biotech A/S announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination…
Read More...

Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)…
Read More...

Genexine, a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs,…
Read More...

Disc Medicine, Inc. announced that is has entered into an agreement with Mabwell Therapeutics to obtain an exclusive license to a portfolio of monoclonal antibodies targeting TMPRSS6…
Read More...

Oerth’s unique PROTAC protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the…
Read More...